Category Archives: The Charlton Center

World Hepatitis Day (WHD) takes place every year on July 28th, bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. In 2021 the theme is ‘Hepatitis … Continue reading →

Infliximab was launched by Janssen over 20 years ago under the name Remicade.  It continues to be a biologic therapy given by infusion (IV) for many autoimmune conditions including rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn’s, and ulcerative colitis.  In the … Continue reading →

We are all aware of the importance of completing both doses of Covid-19 vaccines to get the best protection.  In light of new variants, the push is on to get second doses as soon as possible.  A recent independent study … Continue reading →

It is very exciting to share the news that many of you with high-risk health conditions, will be eligible to receive your second dose at an earlier time. Check with your local health department about the opportunity to have your … Continue reading →

Charlton Health is always on the lookout for great educational resources to share with our patients. We love sharing the work that the Arthritis Society does as their programming is abundant and readily accessible. Tonight the Arthritis Society is hosting … Continue reading →

This week we are happy to share a great learning opportunity. COVID Discussions is a weekly meeting where a group of Canadian health professionals with expertise in vaccination offer weekly information sessions to answer questions from both the public and … Continue reading →

Recently I was asked if a person’s TNF level could be measured to know if a biologic that lowers TNF is a good treatment for them. I wish it was that easy! Although we can do blood tests for markers of … Continue reading →

In writing this blog, we are all aware that the vaccine distribution continues to be updated.  Phase 2 of vaccine distribution is to include patients who have compromising conditions or treatments that suppress the immune system,  regardless of the person’s … Continue reading →

Charlton Health is proud to announce that the first dose in Canada of the biosimilar adalimumab, known as Amgevita (produced by Amgen), was injected at Charlton Health on February 22, 2021. Five biosimilars of adalimumab were released onto the Canadian market … Continue reading →